Milad Shafizadeh

Milad Shafizadeh


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2021 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
PDF file
MSMoeinadin Safavi
Moeinadin Safavi
VMVahid Mehrtash
Vahid Mehrtash
ZHZohreh Habibi
Zohreh Habibi
MMMasoud Mohammadpour
Masoud Mohammadpour
MAMohammad Taghi Haghi Ashtiani
Mohammad Taghi Haghi Ashtiani
BJBita Jafarzadeh
Bita Jafarzadeh
It is about half a century since free-living amoebae were recognized as pathogenic organisms, but there is still much we should learn about these rare fatal human infectious agents. A recently introduced causative agent of granulomatous amoebic encephalitis, Balamuthia mandrillaris, has been reported in a limited number of countries around the world. A 3-year-old girl was referred to our tertiary hospital because of inability to establish a proper diagnosis. She had been experiencing neurologic complaints including ataxia, altered level of consciousness, dizziness, seizure, and left-sided hemiparesis. The patient's history, physical examination results, and laboratory investigations had led to a wide differential diagnosis. CT scan and magnetic resonance imaging analyses revealed multiple mass lesions. As a result, the patient underwent an intraoperative frozen section biopsy of the brain lesion. The frozen section study showed numerous cells with amoeba-like appearances in the background of mixed inflammatory cells. Medications for free-living amoebic meningoencephalitis were administered. PCR assay demonstrated B. mandrillaris as the pathogenic amoeba. Unfortunately, the patient died 14 days after her admission. To our knowledge, this is the first report of B. mandrillaris meningoencephalitis in the Middle East and the first time we have captured the organism during a frozen-section study.

21 February 2025 in Surgical Neurology International
Verified
Journal Article
Open access
MRMohsen Rostami
Mohsen Rostami
NMNavid Moghadam
Navid Moghadam
MRMilad Rashidbeygi
Milad Rashidbeygi
FRFaramarz Roohollahi
Faramarz Roohollahi
MSMilad Shafizadeh
Milad Shafizadeh
SBSadegh Bagherzadeh
Sadegh Bagherzadeh
Background: Adult spinal deformity (ASD) surgeries often face complications, such as pseudoarthrosis and rod fractures (RFs), particularly at the lumbosacral junction. While transforaminal lumbosacral interbody fusion (TLIF) at L5-S1 is thought to improve outcomes, its efficacy in major ASD surgeries remains unclear. This study aims to compare clinical and radiological outcomes and implant complications in patients undergoing spinopelvic fixation with or without L5-S1 TLIF. Methods: A retrospective cohort study was conducted, including 157 ASD patients who underwent high-grade osteotomies and spinopelvic fixation from 2021 to 2024. Patients were divided into two groups: those with L5-S1 TLIF (C group, n = 71) and those without (NC group, n = 86). Outcomes included rod fracture (RF) rate, sagittal alignment, and patient-reported measures such as the Visual Analog Scale (VAS), Oswestry disability index (ODI), and 36-Item Short Form Survey (SF-36), assessed at baseline, 1, 6, and 12 months postoperatively. Results: RFs were significantly lower in the C group (4% vs. 13%, P = 0.03). Improved postoperative sagittal vertical axis and pelvic tilt were noted in the C group (P < 0.01). Both VAS and ODI scores were significantly better at 6 and 12 months in the C group (P < 0.01), along with higher SF-36 scores. No significant differences in baseline characteristics, estimated blood loss, or operation time were observed. Conclusion: The use of L5-S1 TLIF reduces RF rates, improves sagittal alignment, and clinical outcomes in ASD surgery. Incorporating TLIF at L5-S1 may optimize outcomes without increasing perioperative risks.


7 November 2025 in Cellular and Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
AKAmirhossein Kamroo
Amirhossein Kamroo
AEArash Esmaeili
Arash Esmaeili
KTKiana Tahan
Kiana Tahan
MSMilad Shafizadeh
Milad Shafizadeh
NRNima Rezaei
Nima Rezaei
Glioblastoma multiforme (GBM) is a complex and aggressive central nervous system (CNS) tumor that has a poor prognosis, and restricted therapeutic options are available despite the increasing research conducted. Moreover, the cells in our body package microRNAs, ubiquitous modulators of numerous biological processes, into exosomes for cell-to-cell signaling. Indeed, exosomal miRNAs contribute to several aspects of glioma, such as development, occurrence, metastasis, and immune evasion. Additionally, exosomal miRNAs play a key role in cellular functions and glioma pathogenesis by regulating numerous pathways, including the Wnt/β-catenin, PTEN/PI3K/Akt, EGFR/MAPK, notch signaling, and NF-κB. Notably, exosomal miRNAs are recognized to have promising potential in clinical applications; in fact, exosomal miRNAs are emerging biomarkers for glioma diagnosis and prognosis and are additionally considered as putative therapeutic candidates by inhibiting tumor progression, occurrence, and metastasis. This review presents the current knowledge regarding clinical potential and application of exosomal miRNAs in glioma, as well as the miRNA-mediated regulatory network underlying glioma immunopathogenesis. Graphical Abstract Different aspects of exosomal microRNA (miRNA) in the diagnosis, prognosis, and therapy of glioblastoma multiforme (GBM). Exosomal miRNAs play a multifaceted role in the diagnosis of GBM, predicting the survival outcome of GBM, and as innovative therapeutic measures for GBM. Additionally, exosomal miRNAs are involved in the immunomodulation of GBM, inducing an immunosuppressive status in microglia, macrophages, and myeloid-derived suppressor cells (MDSCs).

6 March 2026 in Surgical Neurology International
Verified
Journal Article
Open access
NDNegin Safari Dehnavi
Negin Safari Dehnavi
FZFatemeh Riyahi Zaniyani
Fatemeh Riyahi Zaniyani
SBSadegh Bagherzadeh
Sadegh Bagherzadeh
AKAlireza Khoshnevisan
Alireza Khoshnevisan
UAUshtar Amin
Ushtar Amin
MSMilad Shafizadeh
Milad Shafizadeh
Background: Spontaneous intracranial hypotension (SIH) is a well-recognized but often underdiagnosed cause of secondary subdural hematoma (SDH), particularly in younger patients who frequently present with bilateral collections. The role of lumbar puncture (LP) remains controversial in this setting, as additional cerebrospinal fluid removal may destabilize intracranial pressure and precipitate or worsen SDH. Methods: We performed a systematic review of SIH cases associated with bilateral SDH. When possible, we reconstructed a patient-level dataset to analyze clinical presentation, LP context, management strategies, and outcomes. We also describe a middle-aged man with orthostatic headache and fever who presented with thin, chronic-appearing bilateral SDH in the setting of SIH. Following a diagnostic LP performed to exclude meningitis, he developed a rapidly progressive, extensive bilateral mixed-density SDH requiring urgent burr-hole evacuation. Results: Fifty-nine studies were included, totaling 485 patients with SIH, of whom 182 had bilateral SDH. From these, we assembled a patient-level cohort of 59 individuals with SIH-associated SDH. The mean age was 47 years, and 81.4% were male. Orthostatic headache was present in 76.3%, whereas coma or stupor occurred in 25.4%. In this cohort, 62.7% had no LP, 30.5% underwent LP only after SDH diagnosis, and 6.8% had clearly post-LP SDH. Management included SDH surgery in 67.8%, epidural blood patch in 67.8%, and open leak repair in 11.9%. The overall SDH recurrence rate was 27.1%, with the highest recurrence (55.6%) in patients who underwent LP after SDH recognition. No deaths were reported. Conclusion: Bilateral SDH in the context of SIH mainly affects younger patients and requires a combined strategy of SDH evacuation (when indicated) and leak-directed therapy. Although true post-LP bilateral SDH appears uncommon, LP may reveal or amplify an already unstable low-pressure state. Given the low certainty and incomplete temporal data in many reports, our findings support cautious consideration and avoidance of routine LP solely to document opening pressure in suspected SIH.

23 February 2026 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
MHMohammad Amin Habibi
Mohammad Amin Habibi
SHSeyed Hesam Hojjat
Seyed Hesam Hojjat
BHBardia Hajikarimloo
Bardia Hajikarimloo
MDMohsen Dashti
Mohsen Dashti
AGAfsaneh Ghasemzadeh
Afsaneh Ghasemzadeh
MSMilad Shafizadeh
Milad Shafizadeh
Anlotinib, a novel multi-target tyrosine kinase inhibitor, has shown promise in improving survival and managing associated complications. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of Anlotinib in patients with high-grade glioma, specifically glioblastoma (GBM). This study was conducted according to the PRISMA guidelines. A systematic search was conducted on PubMed, Embase, Web of Science, and Scopus up to 9 December 2024. The included studies were appraised and assessed for quality and potential bias and further statistical analyses were performed using STATA v.17. A total of 17 studies with 473 patients were recruited, which included 204 patients with GBM. The pooled analysis resulted in a 6-month OS of 67% (95% CI: 42–92%) and a 1-year OS equal to 50% (95% CI: 36–64%) from the Anlotinib treatment. Progression-free survival at 6 months was 61% (95% CI: 46–75%), and at 1 year was 27% (95% CI: 13–41%), also showing similar promising outcomes. The overall response rate (ORR) and disease control rate (DCR) were reported at 55% (95% CI: 44–67%) and 90% (95% CI: 87–94%), respectively. The sub-group analysis revealed that adding anlotinb to temozolomide (TMZ) and radiotherapy had superior outcomes regarding OS, PFS, and DCR. Moreover, the highest ORR and complete response rate were achieved by Anlotinib plus stereotactic radiosurgery. Anlotinib demonstrates considerable efficacy in extending survival and achieving disease control in high-grade glioma patients when added to radiotherapy and TMZ. These findings can support its inclusion in therapeutic regimens, warranting further investigation in large-scale randomized controlled trials.